Madrigal Pharmaceuticals, Inc. MDGL

US Biotechnology

$432.79 ▲ +8.30% (+$33.16)

Open $411.50

Prev Close $399.63

Day Range $402.00 – $438.74

52W Range $353.54 – $615.00

Market Cap $10.05B

Beta -0.99

EPS (TTM) $-5.96

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2007-02-06
Shares Out.	23,100,000
Website	madrigalpharma.com/ ↗
Phone	13026587581
Employees	915
Revenue	$431.3M
Gross Profit	$431.3M
Net Income	$55.4M
Free Cash Flow	-$168.7M
Total Assets	$1.43B
Total Liabilities	$807.4M
Equity	$626.9M

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol MDGL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.